MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 November 2020
Melanoma Institute Australia is proud to announce that MIA’s Co-Medical Directors, Professor Georgina Long AO and Professor Richard Scolyer, as well as MIA Faculty member Associate Professor Alex Menzies and former Faculty member Professor Rick Kefford AM, have been named on the annual Highly Cited Researchers™ 2020 list from Clarivate.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe. It identifies researchers who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade.
Their names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index.
According to Clarivate, 6,167 researchers from more than 60 countries and regions have been recognized this year, with Australian research institutes continuing to punch above their weight. In a country of just 25 million, the number of Australian researchers recognized in 2020 is 305.
MIA Co-Medical Director Professor Georgina Long AO, whose video interview with Clarivate is featured online, said:
“This accolade is recognition of the ground-breaking work being carried out by the entire team at Melanoma Institute Australia as we continue our quest to develop treatments that will ultimately save the lives of all melanoma patients.”
Fellow Co-Medical Director of MIA Professor Richard Scolyer said:
“It is an honour to again be included on this list alongside several other MIA researchers and clinicians. It shows the phenomenal and ongoing impact that MIA’s work and research is having around the world.”
David Pendlebury, Senior Citation Analyst at the Institute for Scientific Information at Clarivate said:
“In the race for knowledge, it is human capital that is fundamental and this list identifies and celebrates exceptional individual researchers from Melanoma Institute Australia who are having a great impact on the research community as measured by the rate at which their work is being cited by others.”
Melanoma Institute Australia is affiliated with The University of Sydney
#HighlyCited2020
Q&A with our Clinical Research Fellow
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
International Clinical Trials Day marked
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
5 minutes with Practice Manager Sherrie D'Souza
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Associate Professor Georgina Long has won the InStyle Women In Style Award
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government's 2015-16 Budget announcements benefit research
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
Professor Thompson made an honorary member of the American Surgical Association
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA® ) has been registered by the TGA
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
MIA's Autumn Newsletter
Our Autumn newsletter has been published and we have our digital version online now.
Professor John Thompson appointed to Australian Academy of Health and Medical Sciences
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Melanoma Institute part of $14m melanoma project grant
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
Melanoma March Bibs
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Q&A with Melanoma March Fundraisers
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.
Research Director Graham Mann explains where Melanoma March funds are going
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.
First patient recruited to the EAGLE FM Trial
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.
Online Comments to the Pharmaceutical Benefits Advisory Committee
You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.
A man of commitment
Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.
Melanoma March has officially launched
Melanoma Institute Australia (MIA) has officially launched the 2015 ‘Melanoma March’ initiative in Melbourne.